CNSY — CERENOME, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1095981 ·
Last close
$0.63
Market Cap
$4.78M
52W High
$19.00
52W Low
$0.43
ADV30
1,540,592
Next earnings
—
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -9,057,000 -9,006,000 14,030,000 2,366,000 8,567,000
Mar 2026 0 — -7,119,000 -6,946,000 19,916,000 3,022,000 7,955,000
Dec 2025 0 — -5,742,000 -5,713,000 16,325,000 4,256,000 12,329,000
Sep 2025 0 — -4,482,000 -4,423,000 18,670,000 13,289,000 13,616,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-22,175,000
Investing CF
$-2,947,000
Financing CF
$25,255,000
CapEx
$-1,374,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.74
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-531,817,000
Inventory
—
Receivables
$1,969,000
ST Investments
$6,221,000
EBIT TTM
$-23,005,000
Pretax Income TTM
$-26,088,000
Interest Exp TTM
$3,083,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,203,000
EBITDA
$-25,945,000
Free Cash Flow
$-13,969,750
Enterprise Value
$-1,331,338
Total Cash
$8,587,000
Total Debt
$44,000
Shares Out
7,589,625
Trailing EPS
$-3.36
Book Value
$0.75
ROE
-614.1%
ROA
-135.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -15,298,000 -22,386,000 16,325,000 12,329,000 3,996,000 -20,775,000
Dec 2024 0 -14,695,000 -12,978,000 6,633,000 15,582,000 -8,949,000 -10,554,000
Dec 2023 0 -13,321,000 -13,316,000 11,388,000 12,736,000 -1,348,000 -12,851,000
Dec 2022 0 -19,712,000 -20,275,000 23,867,000 17,422,000 6,445,000 -12,972,000

TTM Snapshot

Revenues TTM
$4,203,000
NetIncome TTM
$-26,088,000
OpCashFlow TTM
—
Assets (Latest)
$14,030,000
Forward EPS
$-2.48

Peers — same industry

TickerNameMarket CapLastDaily %
PCSA Processa Pharmaceuticals, Inc. $4.84M $1.73 —
LTRN Lantern Pharma Inc. $4.67M $0.37 —
CDT CDT Equity Inc. $4.93M $0.36 —
PULM Pulmatrix, Inc. $5.00M $1.37 —
CMND Clearmind Medicine Inc. $5.13M $3.45 —

News headlines (Yahoo Finance, 1h cache)

Cerenome (CNSY) Q3 2026 Earnings Call Transcript
2026-11-16 20:43 · Yahoo
Cerenome Reports Interim REYOBIQ Repeat-Dosing Data in Leptomeningeal Metastases Study
2026-11-16 13:36 · Yahoo
Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting
2026-11-16 12:30 · Yahoo
Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates
2026-11-13 22:25 · Yahoo
Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress
2026-11-13 22:19 · Yahoo
Cerenome: Q3 Earnings Snapshot
2026-11-13 22:13 · Yahoo
Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
2026-11-12 12:30 · Yahoo
Cerenome Appoints Director Ron Andrews as Chief Business Officer
2026-11-10 12:30 · Yahoo
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
2026-11-04 12:30 · Yahoo
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
2026-10-29 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.